ResearcherUniversity of ZurichNo recent work listed

Patrik Simmler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2883-275X; OpenAlex author ID A5039238875. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper

Papers 3

Mutant SF3B1 promotes malignancy in PDAC. Co-author DOI 10.7554/elife.80683 ↗
SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2022.111266 ↗
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Co-author DOI 10.1016/j.xgen.2022.100095 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gerald Schwank · 3 shared papers, 2022–2023 · strength 0.38
Gunnar Rätsch · 2 shared papers, 2022–2023 · strength 0.27
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Markus Stoffel · 2 shared papers, 2022–2023 · strength 0.27
- Paper Mutant SF3B1 promotes malignancy in PDAC. DOI 10.7554/elife.80683 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Chantal Pauli · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Daniela M. Lenggenhager · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Christian Hirt · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Hagen Klett · 1 shared paper, 2022 · strength 0.11
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
Ilaria Guccini · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.